Isolates of Cryptococcus Neoformans from Non-HIV and Non-Transplant Hospitalized Patients
DOI:
https://doi.org/10.30564/jams.v1i2.36Abstract
A retrospective cross-sectional study for patients with confirmed Cryptococcus neoformans meningitis (CM) in non-HIV-infected and non-transplant hosts in two class-A tertiary hospitals in Guangzhou, China is reported. 181 CM patients were enrolled during the study period, 48% (87/181) of which died. Underlying diseases were risk factor associated with higher mortality, among which diabetes mellitus ranked first for the incidence of CM. The mortality was not related to antifungal drug susceptibility. All strains were considered susceptible to amphotericin B, although interpretative breakpoints for amphotericin B have not yet been established. According to the CLSI guidelines, most of the strains in our study were susceptible to voriconazole, fluconazole, fluorocytosine and dose-dependently susceptible to itraconazle.
Keywords:
Cryptococcus neoformans; Drug resistance; Nosocomial infectionReferences
[1] J.R. Perfect, W.E. Dismukes, F. Dromer, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2010, 50(3):291-322.
[2] B.J. Park, K.A. Wannemuehler, B.J. Marston, et al. Estimation of the Current Global Burden of Cryptococcal Meningitis among Persons Living with HIV/AIDS[J]. AIDS, 2009, 23(4):525-530.
[3] J. Guinea, F. Hagen, T. Pelaez, et al. Antifungal Susceptibility, Serotyping, and Genotyping of Clinical Cryptococcus Neoformans Isolates Collected during 18 Years in a Single Institution in Madrid, Spain[J]. Med Mycol, 2010, 48(7):942-948.
[4] J.S. Tan, J.L. Anderson, C. Watanakunakorn, et al. Neutrophil Dysfunction in Diabetes Mellitus[J]. J Lab Clin Med, 1975, 85(1):26-33.
[5] C. Yoon, R.M. Gulick, D.R. Hoover, et al. Case-control Study of Diabetes Mellitus in HIV-infected Patients[J]. J Acquir Immune Defic Syndr, 2004, 37(4):1464-1469.
[6] E. Canton, A. Espinel-Ingroff, J. Peman. Trends in Antifungal Susceptibility Testing Using CLSI Reference and Commercial Methods[J]. Expert Rev Anti Infect Ther, 2009, 7(1):107-119.
[7] A.M. Almeida, M.T. Matsumoto, L.C. Baeza, et al. Molecular Typing and Antifungal Susceptibility of Clinical Sequential Isolates of Cryptococcus Neoformans from Sao Paulo State, Brazil[J]. FEMS Yeast Res, 2007, 7(1):152-164.
Downloads
Issue
Article Type
License
Copyright and Licensing
The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.
Journal of Advances in Medicine Science publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Advances in Medicine Science agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.
License Policy for Reuse of Third-Party Materials
If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.
Journal Policies on Data Sharing
We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.